April 11, 2026·5 min read·anxiolytic, neuro, russian-research, compound-overview
Selank — a research overview
Synthetic anxiolytic heptapeptide with GABAergic and immunomodulatory roots, clinically approved in Russia for stress and anxiety.
Synthetic anxiolytic heptapeptide with GABAergic and immunomodulatory roots, clinically approved in Russia for stress and anxiety.
Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, where it was synthesized as a modified derivative of tuftsin — an endogenous immune-regulating tetrapeptide found in blood. Unlike Epithalon or MOTS-c, which live in the longevity research space, Selank occupies a distinct niche: clinically approved in Russia as an anxiolytic, with a two-decade track record in human use there.
The regulatory status matters. In Russia, Selank is marketed as a pharmaceutical treatment for anxiety and stress disorders, meaning it has undergone clinical trial frameworks, post-marketing surveillance, and dose-standardization typical of approved drugs. In the West, it remains research-only. This gap between regulatory contexts shapes both the data available and the appropriate framing for readers unfamiliar with Russian pharmacopoeia.
Selank modulates GABAergic and serotonergic neurotransmission — the same targets as benzodiazepines and SSRIs, respectively. But unlike those drug classes, Selank is reported to achieve anxiolytic effects without sedation and without withdrawal liability on discontinuation. The mechanistic explanation involves expression-level changes in enkephalin and BDNF (brain-derived neurotrophic factor), along with modulation of neuropeptide Y, suggesting effects beyond simple GABA potentiation.
The tuftsin ancestry is also relevant. Tuftsin is an immunomodulating peptide that enhances monocyte and neutrophil phagocytosis. Selank retains some of this immunomodulatory activity, with published reports of NK-cell activation and mild shifts in Th1/Th2 balance. Whether the immune component contributes meaningfully to anxiolytic effects is unclear — most of the clinical data focuses on mood and anxiety endpoints, not immune measures.
Selank is administered intranasally in clinical and research protocols — a route that achieves rapid bioavailability with direct access to the CNS, potentially bypassing first-pass hepatic metabolism. Plasma half-life is short (minutes), consistent with other neuropeptides, but CNS effects are reported to persist for hours, suggesting either receptor-level persistence or local CNS depot effects not yet fully characterized.
Intranasal dosing is well-tolerated in the published Russian trials, with minimal systemic side effects at therapeutic doses. Bioavailability varies with nasal mucosa integrity and technique, a consideration for protocol-to-protocol reproducibility.
The majority of clinical trial data on Selank comes from Russian-published work, typically smaller open-label or unblinded designs. The primary endpoints are subjective anxiety scales (State-Trait Anxiety Inventory, Hamilton Anxiety Rating Scale) and mood measures, with reported improvements in anxiety scores and faster onset compared to SSRIs (days vs. weeks). Alongside these mood claims are reports of improved sleep quality and cognitive function in aged cohorts.
The critical caveat: the study designs lack Western-standard blinding, placebo control, and independent verification. This doesn't invalidate the findings, but it means readers should treat the evidence as preliminary signal rather than definitive proof. Direct head-to-head comparison with benzodiazepines or SSRIs in a randomized blinded trial would settle much of the ambiguity around efficacy and tolerability, but such studies do not appear in the English-language literature.
Selank is often discussed alongside Semax (a related Russian-developed neuropeptide acting on the hypothalamic-pituitary-adrenal axis for stress resilience) and other neuromodulatory peptides in cognitive-enhancement and stress-reduction stacks. NeuroForge carries Selank but not Semax, so readers stacking compounds should note that distinction. The mechanistic complementarity between GABAergic Selank and HPA-axis-targeted peptides like Semax is plausible but empirically untested. This compound class is distinct from the sleep-supporting peptides like DSIP discussed in the sleep and longevity guide.
Intranasal protocols typically run 4 to 12 weeks, with dosing once or twice daily. The assumption is that short plasma half-life is compensated by persistent neurological signaling, allowing daily or twice-daily administration rather than the intermittent cycling seen with peptides like Epithalon.
Intranasal peptide administration introduces site-to-site variability in absorption and requires careful technique. Baseline nasal mucosal integrity, concurrent congestion, and timing relative to meals or other intranasal compounds all affect bioavailability. Readers considering Selank should establish a consistent protocol for nasal administration and account for inter-individual variation in CNS penetrance.
Anxiety endpoint selection matters. If the research goal is state anxiety (acute stress response), weekly measurement suffices. If tracking trait anxiety (chronic disposition), monthly or bi-weekly intervals are more appropriate. The literature suggests Selank has effects on both, but distinguishing them requires endpoint specificity.
Selank is NeuroForge's primary intranasal anxiolytic option, with the longest regulatory and clinical history in Russia and a mechanistic profile distinct from GABA agonists or SSRI-class compounds. Readers comparing Selank to other neuromodulatory peptides should note: it has real clinical use-data from decades of Russian prescription, the Western replication base is thin, and the intranasal route is both a pharmacokinetic advantage and a technical consideration for home protocols. For readers new to peptide research methods, the reading peptide literature guide helps distinguish between open-label Russian trials and Western-standard randomized designs.
How fast does Selank work for anxiety? Russian clinical data reports anxiolytic effects within days, faster than SSRIs (which take weeks). The intranasal route provides rapid CNS penetration, though Western replication of these timelines is limited.
Is Selank safer than benzodiazepines? Published Russian trials report anxiolytic effects without sedation and no withdrawal liability on discontinuation, contrasting benzodiazepines. However, direct head-to-head blinded comparison in Western trials is absent.
What does intranasal administration mean? Selank is applied as a spray to the nasal mucosa, allowing direct access to the CNS and bypassing hepatic first-pass metabolism. Bioavailability varies with nasal mucosal integrity and technique, requiring consistent protocol.
Can you take Selank with SSRIs or other medications? Published interaction studies are limited. Selank modulates GABAergic and serotonergic pathways, so concurrent SSRI or benzodiazepine use should be approached cautiously and ideally under medical supervision.
